Egetis Therapeutics (EGTX) Q1 2026 earnings summary

Executive summary

• FDA accepted the NDA for Emcitate for MCT8 deficiency, granting Priority Review with a PDUFA date of September 28, 2026; U.S. launch preparations are on track for Q4 2026.

• Emcitate is the first and only approved treatment for MCT8 deficiency in the EU, with commercialization and access expansion ongoing across Europe.

• Oversubscribed SEK 350 million (USD 38 million) share issue completed, strengthening cash position for launches and pipeline development.

• U.S. commercialization preparations accelerated, including expanded early access programs and patient identification.

• Appointment of Tiago Nunes as Chief Medical Officer and new board members to strengthen leadership.

Financial highlights

• Q1 2026 revenue was SEK 13.4 million, up 9% year-over-year at constant exchange rates.

• Net loss for Q1 2026 was SEK -94.5 million, compared to SEK -62.9 million in Q1 2025, reflecting increased U.S. investments.

• Gross profit for Q1 2026 was SEK -0.2 million due to non-cash R&D depreciation; adjusted gross margin was 74%.

• Cash position at quarter-end was SEK 142.5 million, down from SEK 272.8 million a year earlier.

• Operating expenses sequentially decreased by SEK 32 million, mainly due to reduced R&D costs.

Outlook and guidance

• U.S. Emcitate launch expected in Q4 2026, pending FDA approval, with launch readiness activities progressing.

• Priority Review Voucher anticipated upon approval, with recent PRVs selling for USD 150–200 million.

• Q2 2026 revenue expected to exceed Q1, driven by resolution of German reimbursement and broader market access.

• Expansion into additional indications and geographies planned; pivotal study for RTH-beta indication to start in 2027.

• Focus on optimizing European pricing and reimbursement, especially in Germany.